Gregory Byrd, MD
Urology · Wichita, KSNPI 1376619734
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (37.0%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 74.4% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $9,113 and has fallen 72.2% since, to $2,536 in 2025. Among urology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $81.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- Johnson & Johnson$552
- Boston Scientific$474
- AbbVie$255
- Dendreon Pharmaceuticals LLC$224
- Astellas Pharma US Inc$204
- plus $3K from 33 others
Across 5 payments — averaging $5496.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$27K
What the payments were for
- Travel & lodging$6,48037%
- Food & beverage$5,19530%
- Education$5,86133%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 50 | $13,048 |
| Johnson & Johnson | 26 | $552 |
| Boston Scientific | 9 | $474 |
| AbbVie(2 entities) | 17 | $255 |
| Dendreon Pharmaceuticals LLC | 9 | $224 |
| Astellas Pharma US Inc | 8 | $204 |
| Verity Pharmaceuticals Inc. | 9 | $197 |
| Conmed Corporation | 2 | $178 |
| Janssen Scientific Affairs, LLC | 2 | $168 |
| Pfizer | 8 | $146 |
| Tolmar, Inc. | 1 | $139 |
| Ferring Pharmaceuticals Inc. | 2 | $138 |
| Olympus America Inc. | 5 | $137 |
| Immunitybio, Inc. | 1 | $124 |
| Amgen | 8 | $122 |
| Laborie Medical Technologies Corp. | 1 | $112 |
| Endo Pharmaceuticals Inc. | 8 | $110 |
| Blue Earth Diagnostics | 4 | $99 |
| Myovant Sciences Inc. | 1 | $93 |
| Procept Biorobotics Corporation | 1 | $91 |
| Tolmar Pharmaceuticals, Inc. | 5 | $89 |
| Siemens Medical Solutions USA, Inc. | 2 | $88 |
| Antares Pharma, Inc. | 6 | $84 |
| Calyxo, Inc. | 4 | $78 |
| Clarus Therapeutics Inc. | 1 | $75 |
| Axonics, Inc. | 2 | $67 |
| Bayer | 1 | $65 |
| Neotract Inc. | 1 | $64 |
| Travere Therapeutics, Inc. | 3 | $56 |
| Merck | 3 | $48 |
| Coloplast | 3 | $41 |
| Progenics Pharmaceuticals, Inc. | 2 | $40 |
| Urovant Sciences Inc | 2 | $32 |
| Urogen Pharma, Inc. | 2 | $28 |
| Medtronic | 1 | $17 |
| Teleflex LLC | 1 | $16 |
| Ambu Inc. | 1 | $15 |
| Davol Inc. | 1 | $11 |
| Sun Pharmaceutical Industries Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,787
- DA VINCI SP$5,500
- AMS 700$239
- AIRSEAL$128
- ANKTIVA$124
- ADSTILADRIN$114
- Optilume BPH Drug Coated Balloon Catheter$112
- AMS$112
How this compares
$17,536 in reported general payments places this provider in the 90th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 47 | $855,396 |
| NubeqaDarolutamide | 60 | $817,388 |
| OrgovyxRelugolix | 143 | $379,476 |
| Abiraterone Acetate | 60 | $131,413 |
| MyrbetriqMirabegron | 128 | $74,733 |
| GemtesaVibegron | 98 | $66,771 |
| Tamsulosin Hcl | 701 | $5,986 |
| Solifenacin Succinate | 244 | $5,073 |
| Estradiol | 31 | $2,428 |
| Oxybutynin Chloride ErOxybutynin Chloride | 23 | $2,291 |
| Potassium Citrate ErPotassium Citrate | 36 | $2,138 |
| Finasteride | 279 | $1,918 |
| Trospium Chloride | 57 | $1,604 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 28 | $1,450 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 41 | $1,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $552 | $855,39647 claims |
| BayerNubeqa | $65 | $817,38860 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $168 | $131,41360 claims |
| Astellas Pharma US IncMyrbetriq | $204 | $74,733128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 urology providers in Kansas.
Other urology in Wichita
- Timothy RichardsonWichita$493K
- Philippe NabboutWichita$13K
- Fadi JoudiWichita$12K
- Ayham FarhaWichita$8K
- Jeffrey DavisWichita$8K
- James GilbaughWichita$5K
- Jonathan JensenWichita$4K
- George ZakhariaWichita$3K
- Surendra KollaWichita$3K
- Kahlil SaadWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.